StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference
NEWARK, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM)
announced today that President and CEO Martin McGlynn will present an update
on the Company's programs and operations at the 15th Annual BIO CEO & Investor
Conference to be held February 11-12 in New York City. Mr. McGlynn is
scheduled to speak at 8:30 a.m. Eastern Time on Tuesday, February 12.
A live webcast of the presentation will be available through the Company's
corporate website at
Interested parties are encouraged to connect to the website at least 15
minutes prior to the presentation to ensure adequate time for any software
downloads that may be necessary. A replay will also be accessible for 90 days
through the Company's website.
The BIO CEO & Investor Conference is hosted by the Biotechnology Industry
Organization (BIO) and assembles a select group of established public biotech
companies, top public and private equity investors and members of the
sell-side investment community, to explore the current investment landscape
and opportunities in life sciences. In addition to plenary sessions and panel
discussions on timely business topics and key therapeutic areas, the
conference features presentations by leading biotechnology and pharmaceutical
companies, as well as a number of nonprofit and venture philanthropy
organizations. More information on the conference can be found at
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive interim data for the first patient cohort.The Company is
also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease. StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand.Further information about StemCells
is available at http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at
Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein.These
statements include, but are not limited to, statements regarding the clinical
development of its HuCNS-SC cells; the Company's ability to commercialize drug
discovery and drug development tools; and the future business operations of
the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including those described under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011
and in its subsequent reports on Forms 10-Q and 8-K.
CONTACT: Rodney Young
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.